Johnson & Johnson Says Dexamethasone Reduces Infusion-Related Reactions In Patients With EGFR-Mutated Non-Small Cell Lung Cancer Treated With Intravenous RYBREVANT
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson reports that dexamethasone significantly reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT. The study showed a three-fold reduction in IRRs compared to standard management.
September 10, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's study indicates that dexamethasone reduces infusion-related reactions in patients treated with RYBREVANT, potentially enhancing the drug's appeal and usage.
The study demonstrates a significant improvement in the management of infusion-related reactions for RYBREVANT, which could lead to increased adoption and sales of the drug. This positive development is likely to have a favorable impact on JNJ's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90